Phase II Study of a Reduced-Toxicity ' Submyeloablative ' Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Oct 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Antithymocyte globulin (Primary) ; Busulfan (Primary) ; Fludarabine (Primary)
Indications Haematological malignancies
Focus Adverse reactions; Therapeutic Use

15 May 2012 Actual patient number is 82 according to ClinicalTrials.gov.
15 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
15 May 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com